Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69,596,826
-
Total 13F shares
-
42,778,866
-
Share change
-
+11,992,072
-
Total reported value
-
$612,591,768
-
Put/Call ratio
-
20%
-
Price per share
-
$14.32
-
Number of holders
-
103
-
Value change
-
+$176,400,941
-
Number of buys
-
68
-
Number of sells
-
29
Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q2 2023
As of 30 Jun 2023,
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,778,866 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., Invesco Ltd., BlackRock Inc., Avidity Partners Management LP, Ensign Peak Advisors, Inc, VANGUARD GROUP INC, 683 Capital Management, LLC, and NEA Management Company, LLC.
This page lists
103
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.